Astegolimab is a Monoclonal Antibody owned by F. Hoffmann-La Roche, and is involved in 7 clinical trials, of which 5 were completed, and 2 are ongoing.

Astegolimab (RG-6149, AMG-282) inhibits binding of IL-33 to the ST2 receptor. IL-33 and ST2 play important roles in allergic bronchial asthma. IL-33 contribute to the induction and maintenance of eosinophilic inflammation in the airways by acting on lung fibroblasts by binding to its ST2 receptor. ST2 is a member of the interleukin-1 receptor family and exists in a transmembrane (ST2L) and a soluble form (sST2) due to alternative splicing. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils and basophils, ultimately leading to increased expression of cytokines and chemokines. The drug candidate targets the IL-33 and inhibits its binding to the ST2 receptor thereby alleviates the condition.

The revenue for Astegolimab is expected to reach a total of $311m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Astegolimab NPV Report.

Astegolimab was originated by Amgen and is currently owned by F. Hoffmann-La Roche.

Astegolimab Overview

Astegolimab (RG-6149, AMG-282) is under development for the treatment of atopic dermatitis and chronic obstructive pulmonary disease. The drug candidate is administered subcutaneously or intravenously. The drug candidate is a monoclonal antibody that inhibits binding of IL-33 to the ST2 receptor. It is a new molecular entity (NME). It was also under development for coronavirus disease 2019 (COVID-19) pneumonia, asthma and chronic rhinosinusitis with nasal polyps.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Astegolimab

Report Segments
  • Innovator
Drug Name
  • Astegolimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Ear Nose Throat Disorders
  • Infectious Disease
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.